Pfizer Reaffirms Full-Year 2025 EPS Guidance and Provides Full-Year 2026 Guidance

About this update from Pfizer, Inc.

[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":480,"height":212,"url":"https://media.zenfs.com/en/business-wire.com/9506791c2be3b9269566bc8732d06d18"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/Oa84BaKdVycFQzTN6VeDkA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTQyNDtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/9506791c2be3b9269566bc8732d06d18","width":480,"height":212}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Continued Investment in Pipeline and Acquired Assets in 2026 to Fuel Long-Term Growth","length":85,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Reaffirms Full-Year 2025 Adjusted(1) Diluted EPS Guidance(2) and Revises Full-Year 2025 Revenue Guidance(2) to Approximately $62.0 Billion","length":138,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Full-Year 2026 Revenue Guidance(2) Range of $59.5 to $62.5 Billion","length":66,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Full-Year 2026 Adjusted(1) Diluted EPS Guidance(2) Range of $2.80 to $3.00","length":74,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":363,"olType":false},{"type":"text","content":"NEW YORK, December 16, 2025--(BUSINESS WIRE)--Pfizer Inc. (NYSE:PFE) today provided its full-year 2026 guidance(2) while revising its November 4, 2025 full-year 2025 Revenue guidance(2) and reaffirming all other components of full-year 2025 financial guidance(2). The accompanying presentation can be found at www.pfizer.com/investors.","length":335,"tagName":"p"},{"type":"text","content":"FULL-YEAR 2026 REVENUE GUIDANCE(2)","length":34,"tagName":"p"},{"type":"text","content":"Pfizer anticipates full-year 2026 revenues to be in the range of $59.5 to $62.5 billion, while full-year 2025 revenue guidance(2) is revised to approximately $62.0 billion from the range of $61.0 to $64.0 billion previously. Full-year 2026 revenue guidance(2) includes the expectation of revenues from our COVID-19 products being approximately $1.5 billion lower than what is expected in 2025 plus an expected year-over-year negative revenue impact of approximately $1.5 billion due to certain products experiencing loss of exclusivity (LOE)(2). Pfizer expects full-year 2026 operational(3) revenue growth at the midpoi...

More updates from Pfizer, Inc.